secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2026-10-01T20:49:37+00:00
Accession:  0001193125-26-410781
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Achieve Life Sciences appoints Benjamin Halladay CFO effective Oct. 5, 2026; Mark Oki steps down
--------------------------------------------------------------------------------

- Benjamin Halladay appointed CFO and principal financial officer effective Oct. 5, 2026; he was most recently CFO of Esperion Therapeutics from Nov. 2022 to Sept. 2026.
- Halladay's compensation includes a $525,000 annual base salary, a discretionary bonus up to 40% of salary, 200,000 stock options and 200,000 RSUs.
- Mark Oki stepped down as CFO effective Oct. 5, 2026; the company said his departure was not due to disagreement over financial statements or disclosures.
- Halladay severance: nine months of base salary, or 12 months plus prorated bonus and accelerated option/RSU vesting if tied to a change in control.
- Oki will receive severance under his Executive Employment Agreement dated Dec. 5, 2024, filed as Ex. 10.19 to the company's 2024 Form 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000119312526410781/0001193125-26-410781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000119312526410781/achv-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-410781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer